Roche, Basel, Switzerland, and Sysmex, Kobe, Japan, have signed a Global Business Partnership Agreement (GBP) under which they have renewed their commitment to the long-standing agreement that allows Roche to continue to distribute Sysmex hematology products, including instruments and reagents.
The GBP introduces an IT Solutions Collaboration Agreement, in which the two companies have agreed to utilize their respective information technology (IT) platforms to improve customer experience, in the short to mid-term, with a longer term ambition to use the IT systems to lead to improved clinical decision making. The GBP agreement will run until the end of 2030.
“Roche is committed to supporting improvements in hematology testing, which helps patients with the diagnosis and management of blood diseases, as diverse as anemia and leukemia,” says Thomas Schinecker, CEO of Roche Diagnostics. “Extending our longstanding partnership with Sysmex underscores our unique synergy and our objective to offer our customers high-quality haematology solutions to improve the testing efficiency in central laboratories in hospitals and commercial laboratories, ultimately benefiting the millions of patients living with blood disorders.”
